The lifetime risk of developing CRC differs per gPV, ranging from 40 to 50% for patients carrying gPVs in MLH1 or MSH2 genes to 10–20% in MSH6 and PMS2 genes [5, 6]. The gene discussed is MSH2; the disease is colorectal carcinoma.